New trends in current menopausal hormone therapy

The article presents the results of recent studies on the effectiveness, safety and duration of menopausal hormone therapy (MHT). The main cardio-metabolic risk factors for cardiovascular diseases are formed in women precisely during the transition to menopause and are clearly associated with the ap...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vera E. Balan, Elena V. Tikhomirova, Anastasia S. Zhuravel, Julia P. Titchenko, Tatyana V. Lovygina
Formato:	article
Lenguaje:	RU
Publicado:	IP Berlin A.V. 2021
Materias:	menopausal hormone therapy low doses of estrogen menopause Gynecology and obstetrics RG1-991
Acceso en línea:	https://doaj.org/article/9f1c25d909df414d8c952c490b21b8cb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9f1c25d909df414d8c952c490b21b8cb
record_format	dspace
spelling	oai:doaj.org-article:9f1c25d909df414d8c952c490b21b8cb2021-12-02T19:22:24ZNew trends in current menopausal hormone therapy2079-56962079-583110.26442/20795696.2021.1.200635https://doaj.org/article/9f1c25d909df414d8c952c490b21b8cb2021-03-01T00:00:00Zhttps://gynecology.orscience.ru/2079-5831/article/viewFile/63627/46624https://doaj.org/toc/2079-5696https://doaj.org/toc/2079-5831The article presents the results of recent studies on the effectiveness, safety and duration of menopausal hormone therapy (MHT). The main cardio-metabolic risk factors for cardiovascular diseases are formed in women precisely during the transition to menopause and are clearly associated with the appearance of vegetative menopausal symptoms and the development of endothelial dysfunction, which is a predictor of future serious health problems, especially cardiovascular diseases. The results of a number of epidemiological studies have shown that in women with severe climacteric manifestations, especially with hot flashes, the overall risk of developing cardiovascular diseases is increased. The need for early initiation of MHT is an indisputable truth and is not disputed by anyone, but the formed tendency to discontinue treatment in 56 years raises many questions among patients and their doctors. However, recent guidelines from the International Menopause Society state that there is no reason to arbitrarily limit the duration of MHT. This paper presents current evidence on the indications and benefits of low and ultra-low doses of MHT. In view of the high efficacy and safety of low doses of MHT, they seem to be the most acceptable starting doses of oral MHT for most women. In addition, women with early menopause should also receive higher doses of estrogens, as they are more physiological for them. The choice in favor of starting MHT in a postmenopausal woman with a low or ultra-low dose in each case should be selected individually.Vera E. BalanElena V. TikhomirovaAnastasia S. ZhuravelJulia P. TitchenkoTatyana V. LovyginaIP Berlin A.V. articlemenopausal hormone therapylow doses of estrogenmenopauseGynecology and obstetricsRG1-991RUГинекология, Vol 23, Iss 1, Pp 33-36 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	menopausal hormone therapy low doses of estrogen menopause Gynecology and obstetrics RG1-991
spellingShingle	menopausal hormone therapy low doses of estrogen menopause Gynecology and obstetrics RG1-991 Vera E. Balan Elena V. Tikhomirova Anastasia S. Zhuravel Julia P. Titchenko Tatyana V. Lovygina New trends in current menopausal hormone therapy
description	The article presents the results of recent studies on the effectiveness, safety and duration of menopausal hormone therapy (MHT). The main cardio-metabolic risk factors for cardiovascular diseases are formed in women precisely during the transition to menopause and are clearly associated with the appearance of vegetative menopausal symptoms and the development of endothelial dysfunction, which is a predictor of future serious health problems, especially cardiovascular diseases. The results of a number of epidemiological studies have shown that in women with severe climacteric manifestations, especially with hot flashes, the overall risk of developing cardiovascular diseases is increased. The need for early initiation of MHT is an indisputable truth and is not disputed by anyone, but the formed tendency to discontinue treatment in 56 years raises many questions among patients and their doctors. However, recent guidelines from the International Menopause Society state that there is no reason to arbitrarily limit the duration of MHT. This paper presents current evidence on the indications and benefits of low and ultra-low doses of MHT. In view of the high efficacy and safety of low doses of MHT, they seem to be the most acceptable starting doses of oral MHT for most women. In addition, women with early menopause should also receive higher doses of estrogens, as they are more physiological for them. The choice in favor of starting MHT in a postmenopausal woman with a low or ultra-low dose in each case should be selected individually.
format	article
author	Vera E. Balan Elena V. Tikhomirova Anastasia S. Zhuravel Julia P. Titchenko Tatyana V. Lovygina
author_facet	Vera E. Balan Elena V. Tikhomirova Anastasia S. Zhuravel Julia P. Titchenko Tatyana V. Lovygina
author_sort	Vera E. Balan
title	New trends in current menopausal hormone therapy
title_short	New trends in current menopausal hormone therapy
title_full	New trends in current menopausal hormone therapy
title_fullStr	New trends in current menopausal hormone therapy
title_full_unstemmed	New trends in current menopausal hormone therapy
title_sort	new trends in current menopausal hormone therapy
publisher	IP Berlin A.V.
publishDate	2021
url	https://doaj.org/article/9f1c25d909df414d8c952c490b21b8cb
work_keys_str_mv	AT veraebalan newtrendsincurrentmenopausalhormonetherapy AT elenavtikhomirova newtrendsincurrentmenopausalhormonetherapy AT anastasiaszhuravel newtrendsincurrentmenopausalhormonetherapy AT juliaptitchenko newtrendsincurrentmenopausalhormonetherapy AT tatyanavlovygina newtrendsincurrentmenopausalhormonetherapy
_version_	1718376754543853568

New trends in current menopausal hormone therapy

Ejemplares similares